Titel

Merkliste
1 Ergebnisse

Certolizumab Pegol zur Behandlung von Psoriasis-Arthritis: ..:

Wollenhaupt, J ; Mease, P ; Fleischmann, R...
Mease P, Deodhar A, Fleischmann R, Wollenhaupt J, Gladman D, Leszczynski P, Vitek P, Turkiewicz A, Khraishi M, FitzGerald O, Landewé R, de Longueville M, Hoepken B, Peterson L, van der Heijde D. Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure. RMD Open. 2015 Jun 25;1(1):e000119. DOI:10.1136/rmdopen-2015-000119. , 2016

Link: https://doi.org/10.3205/16dgrh301

RT Journal
T1 <Title>Certolizumab Pegol zur Behandlung von Psoriasis-Arthritis: 4-Jahres Ergebnisse aus der RAPID-PSA-Studie</Title>

UL https://suche.suub.uni-bremen.de/peid=base-ftgms:oai:oai-gms.dimdi.de:GM16dgrh301&Exemplar=1&LAN=DE
				
A1 Wollenhaupt, J
A1 Mease, P
A1 Fleischmann, R
A1 Deodhar, A
A1 Gladman, D
A1 Bengt, H
A1 Peterson, L
A1 van der Heijde, D
PB German Medical Science GMS Publishing House; Düsseldorf
YR 2016
K1 Cerolizumab Pegol
K1 Langzeitwirksamkeit
K1 Psoriasis Arthritis
K1 RAPID-PsA
K1 TNF-Blocker
K1 ddc: 610
JF Mease P, Deodhar A, Fleischmann R, Wollenhaupt J, Gladman D, Leszczynski P, Vitek P, Turkiewicz A, Khraishi M, FitzGerald O, Landewé R, de Longueville M, Hoepken B, Peterson L, van der Heijde D. Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure. RMD Open. 2015 Jun 25;1(1):e000119. DOI:10.1136/rmdopen-2015-000119
LK http://dx.doi.org/https://doi.org/10.3205/16dgrh301
DO https://doi.org/10.3205/16dgrh301
SF ELIB - SuUB Bremen

Export

RefWorks (nur Desktop-Version!)
Flow (Zuerst in Flow einloggen, dann importieren)